Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. 30898650 2019
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. 30422115 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE Together, these results suggest that Pim1 contributes to proliferation and gly-colysis in OC via interaction with MYC and may serve as a potential target in the treatment of OC patients. 30349298 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE Thus, hindering not only mt-rRNA transcription, but also mitoribosome function in MYC-overexpressing ovarian (cancer) cells, potentiates the antiproliferative effect of CX-5461. 29435159 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 AlteredExpression disease BEFREE EPHA1 may play a role in OC through its regulation of multiple signaling pathways, such as matrix metalloproteinase-2 (MMP2), extracellular signal-regulated kinase 2 (ERK2) and proto-oncogene c-MYC. 28739735 2017
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis. 27483433 2016
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE These findings identify c-MYC as a potential therapeutic target for ovarian cancers expressing high levels of this oncoprotein. 26227489 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE The objective of the study was to evaluate the prognostic effect of p53, p27, and C-MYC on clinicopathological features, recurrent disease, and disease-free survival (DFS) of 131 patients with ovarian cancer in International Federation of Gynecology and Obstetrics (FIGO) stages I-II. 21270607 2011
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease CTD_human Analysis of HOXD1, MYC, TIPARP and SKAP1 at these loci and of BNC2 at 9p22 supports a functional role for these genes in ovarian cancer development. 20852632 2010
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE The MYCC (c-MYC) gene is amplified in 30-60% of human ovarian cancers. 20647308 2010
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. 15132769 2004
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 AlteredExpression disease BEFREE Using oligonucleotide microarrays, L-MYC was found to be more frequently overexpressed in OvCas than either c-MYC or N-MYC relative to ovarian surface epithelium. 12707044 2003
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.400 Biomarker disease BEFREE MYC DNA amplification was seen in 33.8% (26/77 cases) of ovarian carcinoma. 8972757 1996